1987
DOI: 10.1097/00005344-198706107-00032
|View full text |Cite
|
Sign up to set email alerts
|

Improved Renal Function During Chronic Lisinopril Treatment in Moderate to Severe Primary Hypertension

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

1
3
0

Year Published

1990
1990
2016
2016

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(4 citation statements)
references
References 0 publications
1
3
0
Order By: Relevance
“…As in another study [6], we observe no change in cardiac output after lisinopril. On the contrary, Gara- vaglia et al [7] report a significant decrease in cardiac output during lisinopril monotherapy, which they attribute to a decrease in venous tone, as suggested by a redistribution of the intravascular volume from the cardiopulmonary area to the periphery.…”
Section: Discussionsupporting
confidence: 82%
See 2 more Smart Citations
“…As in another study [6], we observe no change in cardiac output after lisinopril. On the contrary, Gara- vaglia et al [7] report a significant decrease in cardiac output during lisinopril monotherapy, which they attribute to a decrease in venous tone, as suggested by a redistribution of the intravascular volume from the cardiopulmonary area to the periphery.…”
Section: Discussionsupporting
confidence: 82%
“…Other studies have reported a more striking significant increase in renal plasma flow during long-term lisinopril administration [6,7]. In these conditions, BP is significantly decreased and the only other significant change observed is a reduction in RVRI.…”
Section: Discussionmentioning
confidence: 82%
See 1 more Smart Citation
“…Though clearly sufficient to permit reasonably firm conclusions about common renal mechanisms of action of antihypertensive drugs, studies in humans of the renal hemodynamic effects over extended periods would benefit from being more rigorous and numerous. Many have been motivated by an attempt to display “favorable” renal effects, by which is usually meant no reduction in GFR or RBF (Textor et al, 1982 ; Bauer, 1984 ; Sugino et al, 1984 ; Dupont et al, 1987 ; Smith et al, 1987 ; Reams et al, 1988 ; Degaute et al, 1992 ; De Rosa et al, 2002 ), when it is clear that neither of these is a prerequisite for clinical efficacy. Furthermore, some studies misleadingly identify a fall in RVR as contributing to an antihypertensive effect only in proportion to the contribution this fall makes to the decrease in overall SVR (Koshy et al, 1977 ; Preston et al, 1979 ; Warren et al, 1981 ; Thananopavarn et al, 1982 ; Bauer, 1984 ; Dupont et al, 1987 ; Smith et al, 1987 ; van den Meiracker et al, 1989 ; Fridman et al, 2000 ).…”
Section: Discussionmentioning
confidence: 99%